secukinumab 150 mg + placebo to secukinumab 150 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Plaque-type Psoriasis
Conditions
Moderate to Severe Plaque-type Psoriasis
Trial Timeline
Jun 1, 2011 → Apr 1, 2013
NCT ID
NCT01365455About secukinumab 150 mg + placebo to secukinumab 150 mg
secukinumab 150 mg + placebo to secukinumab 150 mg is a phase 3 stage product being developed by Novartis for Moderate to Severe Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01365455. Target conditions include Moderate to Severe Plaque-type Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01365455 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Plaque-type Psoriasis